Covalent dimer species of beta-defensin Defr1 display potent antimicrobial activity against multidrug-resistant bacterial pathogens. 2007

Karen Taylor, and Bryan McCullough, and David J Clarke, and Ross J Langley, and Tali Pechenick, and Adrian Hill, and Dominic J Campopiano, and Perdita E Barran, and Julia R Dorin, and John R W Govan
Medical Research Council Human Genetics Unit, Western General Hospital, Edinburgh, Scotland, UK.

Beta defensins comprise a family of cationic, cysteine-rich antimicrobial peptides, predominantly expressed at epithelial surfaces. Previously we identified a unique five-cysteine defensin-related peptide (Defr1) that, when synthesized, is a mixture of dimeric isoforms and exhibits potent antimicrobial activity against Escherichia coli and Pseudomonas aeruginosa. Here we report that Defr1 displays antimicrobial activity against an extended panel of multidrug-resistant nosocomial pathogens for which antimicrobial treatment is limited or nonexistent. Defr1 fractions were collected by high-pressure liquid chromatography and analyzed by gel electrophoresis and mass spectrometry. Antimicrobial activity was initially investigated with the type strain Pseudomonas aeruginosa PAO1. All fractions tested displayed equivalent, potent antimicrobial activity levels comparable with that of the unfractionated Defr1. However, use of an oxidized, monomeric six-cysteine analogue (Defr1 Y5C), or of reduced Defr1, gave diminished antimicrobial activity. These results suggest that the covalent dimer structure of Defr1 is crucial to antimicrobial activity; this hypothesis was confirmed by investigation of a synthetic one-cysteine variant (Defr1-1cys). This gave an activity profile similar to that of synthetic Defr1 but only in an oxidized, dimeric form. Thus, we have shown that covalent, dimeric molecules based on the Defr1 beta-defensin sequence demonstrate antimicrobial activity even in the absence of the canonical cysteine motif.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D001419 Bacteria One of the three domains of life (the others being Eukarya and ARCHAEA), also called Eubacteria. They are unicellular prokaryotic microorganisms which generally possess rigid cell walls, multiply by cell division, and exhibit three principal forms: round or coccal, rodlike or bacillary, and spiral or spirochetal. Bacteria can be classified by their response to OXYGEN: aerobic, anaerobic, or facultatively anaerobic; by the mode by which they obtain their energy: chemotrophy (via chemical reaction) or PHOTOTROPHY (via light reaction); for chemotrophs by their source of chemical energy: CHEMOLITHOTROPHY (from inorganic compounds) or chemoorganotrophy (from organic compounds); and by their source for CARBON; NITROGEN; etc.; HETEROTROPHY (from organic sources) or AUTOTROPHY (from CARBON DIOXIDE). They can also be classified by whether or not they stain (based on the structure of their CELL WALLS) with CRYSTAL VIOLET dye: gram-negative or gram-positive. Eubacteria
D019281 Dimerization The process by which two molecules of the same chemical composition form a condensation product or polymer. Dimerizations
D023083 beta-Defensins DEFENSINS found mainly in epithelial cells. beta-Defensin,beta Defensin,beta Defensins
D024901 Drug Resistance, Multiple, Bacterial The ability of bacteria to resist or to become tolerant to several structurally and functionally distinct drugs simultaneously. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Drug Resistance, Extensive, Bacterial,Drug Resistance, Extensively, Bacterial,Extensive Antibacterial Drug Resistance,Extensively Antibacterial Drug Resistance,Multidrug Resistance, Bacterial,Multiple Antibacterial Drug Resistance,Bacterial Multidrug Resistance,Bacterial Multidrug Resistances,Resistance, Bacterial Multidrug

Related Publications

Karen Taylor, and Bryan McCullough, and David J Clarke, and Ross J Langley, and Tali Pechenick, and Adrian Hill, and Dominic J Campopiano, and Perdita E Barran, and Julia R Dorin, and John R W Govan
January 2012, Platelets,
Karen Taylor, and Bryan McCullough, and David J Clarke, and Ross J Langley, and Tali Pechenick, and Adrian Hill, and Dominic J Campopiano, and Perdita E Barran, and Julia R Dorin, and John R W Govan
November 2018, ChemMedChem,
Karen Taylor, and Bryan McCullough, and David J Clarke, and Ross J Langley, and Tali Pechenick, and Adrian Hill, and Dominic J Campopiano, and Perdita E Barran, and Julia R Dorin, and John R W Govan
August 2023, Infectious disease reports,
Karen Taylor, and Bryan McCullough, and David J Clarke, and Ross J Langley, and Tali Pechenick, and Adrian Hill, and Dominic J Campopiano, and Perdita E Barran, and Julia R Dorin, and John R W Govan
March 2021, Pharmaceutics,
Karen Taylor, and Bryan McCullough, and David J Clarke, and Ross J Langley, and Tali Pechenick, and Adrian Hill, and Dominic J Campopiano, and Perdita E Barran, and Julia R Dorin, and John R W Govan
December 2017, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
Karen Taylor, and Bryan McCullough, and David J Clarke, and Ross J Langley, and Tali Pechenick, and Adrian Hill, and Dominic J Campopiano, and Perdita E Barran, and Julia R Dorin, and John R W Govan
April 2024, Contact lens & anterior eye : the journal of the British Contact Lens Association,
Karen Taylor, and Bryan McCullough, and David J Clarke, and Ross J Langley, and Tali Pechenick, and Adrian Hill, and Dominic J Campopiano, and Perdita E Barran, and Julia R Dorin, and John R W Govan
August 2021, ACS synthetic biology,
Karen Taylor, and Bryan McCullough, and David J Clarke, and Ross J Langley, and Tali Pechenick, and Adrian Hill, and Dominic J Campopiano, and Perdita E Barran, and Julia R Dorin, and John R W Govan
April 2023, International journal of molecular sciences,
Karen Taylor, and Bryan McCullough, and David J Clarke, and Ross J Langley, and Tali Pechenick, and Adrian Hill, and Dominic J Campopiano, and Perdita E Barran, and Julia R Dorin, and John R W Govan
August 2015, Current microbiology,
Karen Taylor, and Bryan McCullough, and David J Clarke, and Ross J Langley, and Tali Pechenick, and Adrian Hill, and Dominic J Campopiano, and Perdita E Barran, and Julia R Dorin, and John R W Govan
January 2014, PloS one,
Copied contents to your clipboard!